Mexiletine overdosage: Difference between revisions
(Created page with "__NOTOC__ {{Mexiletine}} {{CMG}}; {{AE}} {{SS}} ==Overdosage== Clinical findings associated with mexiletine overdosage have included drowsiness, confusion, [[nausea]...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
==Overdosage== | ==Overdosage== | ||
Clinical findings associated with mexiletine overdosage have included [[drowsiness]], [[confusion]], [[nausea]], [[hypotension]], [[sinus bradycardia | Clinical findings associated with mexiletine overdosage have included [[drowsiness]], [[confusion]], [[nausea]], [[hypotension]], [[sinus bradycardia]], [[paresthesia]], [[seizures]], [[bundle branch block]], AV heart block, [[asystole]], [[ventricular tachyarrythmia]], including [[ventricular fibrillation]], [[cardiovascular collapse]] and [[coma]]. The lowest known dose in a fatality case was 4.4 g with postmortem serum mexiletine level of 34 to 37 mcg/mL (Jequier P. et. al., Lancet 1976: 1 (7956): 429). Patients have recovered from ingestion of 4 g to 18 g of mexiletine (Frank S. E. et. al., Am J Emerg Med 1991: 9:43-48). | ||
There is no specific antidote for mexiletine. Management of mexiletine overdosage includes general supportive measures, close observation and monitoring of vital signs. In addition, the use of pharmacologic interventions (e.g., pressor agents, [[atropine]] or [[anticonvulsants]]) or transvenous cardiac pacing is suggested, depending on the patient’s clinical condition.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MEXILETINE HYDROCHLORIDE CAPSULE [TEVA PHARMACEUTICALS USA INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=693da40b-26d4-40d6-87d1-158e256f40ab | publisher = | date = | accessdate = 3 March 2014 }}</ref> | There is no specific antidote for mexiletine. Management of mexiletine overdosage includes general supportive measures, close observation and monitoring of vital signs. In addition, the use of pharmacologic interventions (e.g., pressor agents, [[atropine]] or [[anticonvulsants]]) or transvenous cardiac pacing is suggested, depending on the patient’s clinical condition.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MEXILETINE HYDROCHLORIDE CAPSULE [TEVA PHARMACEUTICALS USA INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=693da40b-26d4-40d6-87d1-158e256f40ab | publisher = | date = | accessdate = 3 March 2014 }}</ref> | ||
Revision as of 15:55, 10 March 2014
| Mexiletine |
|---|
| MEXILETINE HYDROCHLORIDE® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Mexiletine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Overdosage
Clinical findings associated with mexiletine overdosage have included drowsiness, confusion, nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, AV heart block, asystole, ventricular tachyarrythmia, including ventricular fibrillation, cardiovascular collapse and coma. The lowest known dose in a fatality case was 4.4 g with postmortem serum mexiletine level of 34 to 37 mcg/mL (Jequier P. et. al., Lancet 1976: 1 (7956): 429). Patients have recovered from ingestion of 4 g to 18 g of mexiletine (Frank S. E. et. al., Am J Emerg Med 1991: 9:43-48).
There is no specific antidote for mexiletine. Management of mexiletine overdosage includes general supportive measures, close observation and monitoring of vital signs. In addition, the use of pharmacologic interventions (e.g., pressor agents, atropine or anticonvulsants) or transvenous cardiac pacing is suggested, depending on the patient’s clinical condition.[1]
References
- ↑ "MEXILETINE HYDROCHLORIDE CAPSULE [TEVA PHARMACEUTICALS USA INC]". Retrieved 3 March 2014.